Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dare Bioscience Inc (NQ: DARE )

1.355 -0.005 (-0.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,040
Open 1.355
Bid (Size) 1.330 (20)
Ask (Size) 1.350 (6)
Prev. Close 1.360
Today's Range 1.355 - 1.355
52wk Range 0.8200 - 1.880
Shares Outstanding 70,521,979
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Daré Bioscience Shares Move Higher Intravaginal Ring Shows Promise In Menopause Symptoms
 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Dare Bioscience: Here's What You Need To Know
 
Via Benzinga

Performance

YTD
+56.18%
+56.18%
1 Month
+63.25%
+63.25%
3 Month
+39.69%
+39.69%
6 Month
+25.46%
+25.46%
1 Year
-13.69%
-13.69%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Daré Bioscience's Intravaginal Ring Improves Vasomotor, Vaginal Symptoms Of Menopause
Via Benzinga
Dare Bioscience: Q1 Earnings Insights
Via Benzinga
Recap: Dare Bioscience Q4 Earnings
Via Benzinga
Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Via Benzinga
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
Via TheNewswire.com
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
Via News Direct
Can This Company's Birth Control Patch Disrupt The Contraceptive Market?
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Via Benzinga
Earnings Outlook For Dare Bioscience
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
President Biden Mulls Health Emergency For Abortion Access: Report
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision
Via InvestorPlace
3 Women's Health Stocks Are Soaring Following Roe v. Wade Ruling
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
Earnings Preview: Dare Bioscience
Via Benzinga
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
Via Benzinga
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
From Organon & Co.
Via Business Wire
Earnings Preview: Dare Bioscience
Via Benzinga
Earnings Scheduled For March 31, 2022
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.